SCHEMBL3336033

SCHEMBL3336033

CCOc1nc(N)nc2ccc(-c3ccoc3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 1/20 0.46
HRH4 Q9H3N8 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
ADORA2A P29274 1/20 0.45
CLK4 Q9HAZ1 14/20 0.44
ALDH1A1 P00352 13/20 0.44
CYP1A2 P05177 12/20 0.44
CYP3A4 P08684 10/20 0.44
CYP2D6 P10635 9/20 0.44
LMNA P02545 7/20 0.44
CYP2C19 P33261 6/20 0.44
MAPK1 P28482 5/20 0.44
USP2 O75604 10/20 0.43
HSD17B10 Q99714 7/20 0.43
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
CASP1 P29466 1/20 0.43
CYP2C9 P11712 2/20 0.41
TSHR P16473 5/20 0.41
AAK1 Q2M2I8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3331148 0.83 DHFR (0.48) ALDH1A1LMNAMAPK1HSD17B10MEN1
SCHEMBL3337055 0.82 HRH1 (0.46) HRH1HRH4HRH3ADORA2ACLK4
SCHEMBL3334236 0.82 HSP90AB1 (0.50) ADORA2AALDH1A1MAPK1HSD17B10MEN1
SCHEMBL3337900 0.82 TRIM58 (0.43) HRH1HRH4HRH3ADORA2ACLK4
SCHEMBL3337583 0.81 MAP4K4 (0.47) ADORA2AALDH1A1MAPK1AAK1DHFR
SCHEMBL3336519 0.81 ESR1 (0.41) ALDH1A1LMNAMAPK1MEN1KMT2A
SCHEMBL3340999 0.80 DHFR (0.40) ADORA2AALDH1A1MAPK1MEN1KMT2A
SCHEMBL3336846 0.79 ADORA2A (0.49) HRH1HRH4HRH3ADORA2ACLK4
SCHEMBL3337794 0.79 DHFR (0.48) ALDH1A1MAPK1HSD17B10MEN1KMT2A
SCHEMBL3336155 0.78 CYP1A2 (0.54) HRH1HRH4HRH3ADORA2ACLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 HRH1 124/4885HRH4 18/4885HRH3 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.